Chemical system biology based molecular interactions to identify inhibitors against Q151M mutant of HIV-1 reverse transcriptase.
PMID: 28396546
2017
Antimicrobial agents and chemotherapy
Abstract: Q151M and four associated mutations, A62V, V75I, F77L, and F116Y, were detected in patients failing therapies with dideoxynucleosides (didanosine [ddI], zalcitabine [ddC]) and/or zidovudine (AZT).
Abstract: The cluster of the five mutations is referred to as the Q151M complex (Q151Mc), and an RT or virus containing Q151Mc exhibits resistance to multiple NRTIs.
Abstract: The single mutation Q151M introduces conformational perturbation at the deoxynucleoside triphosphate (dNTP)-binding pocket, and the mutated pocket may exist in multiple conformations.
Abstract: To understand the structural basis for Q151M and Q151Mc
Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals.
Result: Protease (PR) RAMs detected from this outlier sample were M46I, I47V and I84V, and reverse transcriptase (RT) RAMs were A62V, D67N, K70R, V75I, F116Y, Q151M and K219Q.
Result: RT RAMs were A62V, D67N, V75I, F77L, K101H, Y115F, F
Prevalence of Primary HIV Drug Resistance in Thailand Detected by Short Reverse Transcriptase Genotypic Resistance Assay.
Abstract: Fourteen major mutations of codon 99-191 on the RT gene were selected (K103N, V106A/M, V108I, Q151M, Y181C/I, M184V/I, Y188C/L/H, and G190S/A) at a cost of testing of 35 USD.
Method: This region was selected to cover 14 mutations (K103N, V106A/M, V108I, Q151M, Y181C/I, M184V/I, Y188C/L/H, and G190S/A) contributing
Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
Result: AZT resistant HIV-1 strains typically possess TAMs to remove incorporated NRTIs as AZTMP or d4T, whereas the Q151M discrimination pathway usually occurs upon administration of other NRTIs like 3TC and ddI.
Result: Although G190E is a NNRTI resistance mutation, it is often detected with V75I of the Q151M complex.
Result: Finally, in July 2008 four out of six TAMs relevant for highly efficient AZTMP excision (M41L, D67N, T215Y and K219E, missing K70R and L210W) as well as four out of five discrimination mutations (
Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
Introduction: Conventionally, mutations like K69 Insertion, Q151M complex and multiple TAMs reduce susceptibility to all currently available NRTI.
Introduction: In subtype C-infected Indian population, K69 Insertion and Q151M are seldom reported and common mutations responsible for multi-NRTI resistance includes, K65R and multiple TAMs with or without M184V.
Discussion: A similar study from Asia found multi-NRTI resistant associated mutations (RAMs) in 37% of the patients, wherein, multi-NRTI RAMs were defined as presence of either Q151M; 69Ins; 2 TAMs; or M184V + 1 TAM.
Discussion: Due to low prevalence of multi drug
HIV-1 Epidemiology, Genetic Diversity, and Primary Drug Resistance in the Tyumen Oblast, Russia.
Result: The mutation A62V is an accessory mutation that often occurs in combination with the multinucleoside resistance mutations K65R or Q151M.
Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
PMID: 27355415
2016
Journal of acquired immune deficiency syndromes (1999)
Abstract: Resistance mutations in 50 of 73 children with available genotyping at first VF included M184V (56%), >=1 thymidine analogue mutation (TAM; 40%), >=4 TAMs (10%), Q151M (4%), any major LPV mutation (8%), >=6 LPV mutations (2%), and any major ATV mutation (4%).
Result: NRTI mutations included >=1 TAM (40%), >=4 TAMs (10%), T215Y/F (23%), Q151M (4%), M184V (56%), K65R (2%).
High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate.
Abstract: Using a newly developed virus breakthrough assay with TAF exposure set at physiological concentrations, we show that HIV-1 clinical isolates harboring TFV resistance mutations such as K65R, 3 or 4 thymidine-analog mutations (TAMs), Q151M/K65R, or T69 insertion complex could be inhibited by TAF, but not by TFV when used at clinically relevant concentrations for TDF.
Short Communication: In Vitro Accumulation of Drug Resistance Mutations in Chimeric Infectious Clones Containing Subtype B or C Reverse Transcriptase and Selected with Tenofovir or Didanosine.
PMID: 26075306
2015
AIDS research and human retroviruses
Abstract: Both patterns, M184V+K65R and Q151M+K65R, have a significant impact on NRTI resistance.
Abstract: Other primary mutations (M184V and Q151M) were selected with ddI treatment in conjunction with K65R only in RTC' viruses.
Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.
HIV mutation literature information.
PMID: 
2017
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT